CERCETÃRI CLINICO-EPIDEMIOLOGICE ASUPRA COMPLICAȚIILOR CARDIOVASCULARE APÃRUTE LA PACIENȚII CU SINDROM METABOLIC

  • Maria-Magdalena LEON Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • Corina Dima- COZMA Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • Irina JABA Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • D. ILISEI Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
  • F. MITU Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași
Keywords: METABOLIC SYNDROME, CARDIOVASCULAR DISEASE, INCIDENCE, HYPERTENSION, HEART FAILURE

Abstract

Our study aims to
identify correlations between the metabolic syndrome and cardiovascular diseases determinism.
Material and methods: A retrospective study was carried out on a sample of 1463 patients of
which 734 patients met the diagnostic criteria of cardiometabolic syndrome, admitted in the
Clinic of Cardiovascular Rehabilitation, Rehabilitation Hospital, Iasi, between 01.01. 2009-
31.12.2009. Results: The incidence of cardiometabolic syndrome has a soft predominance on
the group 40-59 years (61.66%). The high level of hypertension was found in the patients
group 48-69 years (53.70%) and lowest in the patients group 25-38 years (11.35%) (p=0.001).
The coronary heart diseases showed a significant difference between age groups: 48-69 years
(41.80%), compared to 25-38 years (7.55%) (p=0.003). Heart failure is part of the same age
distribution curve (45%, 6.8%) (p=0.02). Conclusions: The metabolic syndrome is a
predictor of the occurrence and development cardiovascular disease.

Author Biographies

Maria-Magdalena LEON, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Semiologie Medicala

Corina Dima- COZMA, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Semiologie Medicala

Irina JABA, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã

Disciplina de Farmacologie

D. ILISEI, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Semiologie Medicala

F. MITU, Universitatea de Medicină și Farmacie ”Gr. T. Popa” Iași

Facultatea de Medicinã
Disciplina de Semiologie Medicala

References

1. Ursu GF, Mârzan L, ªtiru C, Ursu RI, Apetrei E. Adiponectina ºi insulina în sindromul metabolic.
Revista Românã de Cardiologie 2009; 2: 111-122.
2. Bloomgarden ZT. Insulin Resistance, Dyslipidemia and Cardiovascular Disease. Diabetes Care
2007; 30 (8): 2164-2170.
3. Bruno G, Fornengo P, Segre O et al. What is the clinical usefulness of the metabolic syndrome?
The Casale Monferrato study. J Hypertens 2009; 27 (12): 2403-2408.
4. Gersch C, Palii SP, Kim KM et al. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotidis
Nucleic Acids 2008; 27(8): 967-978.
5. Gaspard U. Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women.
Maturitas 2009; 62(4): 362-365
6. Adrogue H, Madias N. Sodium and Potassium in the Pathogenesis of Hypertension. The New
England Journal of Medicine 2007; 356: 1966-1978.
7. Cai C, Hahn BH, Matarese G, La Cava A. Leptin in non-autoimmune inflammation. Inflammation
and Allergy Drug Targets 2009; 8 (4): 285-291.
8. Vinereanu D, Cinteza M, Pana B et al. Prevalence and control of cardiovascular risk factors in
Romania cardio-zone national study. Maedica 2007; 2(4): 277-288.
9. Farmer J. Diabetic dyslipidemia and atherosclerosis: Evidence from clinical trials. Current
Atherosclerosis Reports 2007; 9(2): 162-168.
10. Indraratna PL, Williams KM, Graham GG, Day RO. Hyperuricemia, cardiovascular disease, and
the metabolic syndrome. J Rheumatol 2009; 36 (12): 2842-2843.
11. Kahn R. Metabolic syndrome. Is it a syndrome? Does it matter. Circulation 2007; 115: 1806-1811.
Published
2019-04-14
Section
INTERNAL MEDICINE - PEDIATRICS